The European Medicines Agency (EMA) on Friday approved a new manufacturing site in France for the production of Moderna Inc's Covid-19 vaccine.
The site at Monts will be operated by Recipharm and produce the finished product, the EMA's committee for human medicines (CHMP) said.
Earlier this month, the CHMP approved two new sites in the United States to produce both active substance and the finished product for Moderna's vaccine.
It expects these moves to allow production of an additional one million to two million vials of ready-to-use vaccine for the European Union market every month.
Moderna already has a deal with Thermo Fisher Scientific's commercial manufacturing site in Greenville, North Carolina that will support production of "hundreds of millions" of doses.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Art Basel fair breathes life back into market
EU to impose universal phone charger, in blow to Apple
UNHCR blasts UK's planned immigration law
US lifting import ban on British lamb, says Johnson
Pakistan calls for unfreezing of Afghan assets ahead of UN talks
EU backs France in submarine dispute, asking: Is America back?
Shock in Germany after cashier shot dead in mask row
Lava engulfs 100 homes in Canary Islands
Eight dead after gunman opens fire on Russian campus